Combination chemotherapy for Hodgkin's disease based upon the MOPP regimen (mustine, vincristine, procarbazine and prednisolone) or its variants will produce complete remission in 60-80% of patients with advanced disease but 20-40% of these will relapse (reviewed by Selby et al., 1987) . The MOPP regimen results in substantial acute toxicity such as nausea, vomiting, hair loss and neuropathy, and also in long term morbidity such as second malignancies and sterility in men (DeVita et al., 1980; Selby et al., 1987; Colman & Selby, 1987; Sutcliffe, 1987) . Variations of the MOPP regimen incorporating alternative alkylating agents or alternative vinca alkaloids substantially reduce the acute toxicity but do not appear to increase the proportion of patients achieving complete remission or who are cured, neither do they remove the risk of leukaemia and infertility (Selby et al., 1990) .
Despite the success of MOPP and its variants, their limitations have led to a search for second line or alternative combination chemotherapy regimens for Hodgkin's disease. Single agents with activity in this disease include adriamycin, bleomycin, dacarbazine and etoposide. The first major development of an effective alternative combination was the ABVD regimen from the Milan Cancer Institute (Bonadonna et al., 1985) ; in a recent survey of the literature the ABVD regimen when used as second line chemotherapy for patients with disease resistant to MOPP, or similar chemotherapy resulted in complete a remission for 75 of 232 patients (32%) . The follow-up available from this study suggests that about one third of the patients achieving CR will remain disease-free for long periods (Santoro et al., 1982) . Although the ABVD regimen is not strongly associated with long-term infertility in males or secondary acute leukaemia, patients who receive this treatment do experience severe acute toxicity with nausea and vomiting and hair loss.
The single agent activity of etoposide ini Hodgkin's disease together with its lack of acute toxicity (Taylor et al., 1982) has led us to develop combinations with this drug. We have used a regimen known as HOPE-Bleo for the treatment of relapsed HD in which adriamycin, vincristine, bleomycin and prednisolone were combined with etoposide. The majority of surviving patients treated with this regimen have been followed up beyond 3 years, which leads us to now report the results.
Patients, materials and methods

Treatment regimen
The regimen is shown in Table I . Treatment was delivered in outpatients, where patients were required to attend on day 1 and day 8. Nadir blood counts (days 10-14) were routinely taken during the first three cycles in order to allow biotitration of the oral dose of etoposide. Treatment was repeated after 3 weeks or when the white cell count exceeded 3 x I09 1-' and platelet count exceeded 100 x 109 1 ', a maximum of eight courses of treatment were given.
Patients Forty-four patients with relapsed or resistant Hodgkin's disease were entered into the study. The study was approved by the institutional ethical review committee and patients gave verbal, witnessed informed consent.
The median age of the patients was 27 years (range 12-71 years), 28 patients were aged 21-40 and only three were over the age of 50; 30 patients were male and 14 female. The histological subtype (Lukes & Butler, 1966) was nodular sclerosis in 31, mixed cellularity in 11, lymphocyte predominance in one and lymphocyte depletion in one patient. Clinical stage at presentation is shown in Table II Statistics Remission rates were compared using non-parametric tests including x2, Fisher's exact probability and Mann-Whitney U tests. Curves for survival and duration of complete remission were calculated according to the method of Kaplan and Meier (1958) . Survival and remission duration were both measured from the date of the first course of treatment.
Results
Forty-four patients received the HOPE-Bleo regimen. Twenty-four received six courses and only three patients received more than six courses. Table V shows the response of patients to HOPE-Bleo. The complete remission rate for all patients was 59%, with 23% partial remissions and 14% non responders. There were two early deaths (day 13 and day 17). In Tables III and IV the response rate is shown according to the number of previous chemotherapy regimens. As expected, the complete remission rate to HOPE-Bleo fell with increasing numbers of previous chemotherapy regimens from 73% for patients who have received only one previous regimen to 0% among the four patients who had received four or more treatments (P = 0.003). Patients who had not previously received adriamycin were more likely to enter complete remission (66% against 25%, P = 0.04) and there was a trend favouring patients who had not previously received etoposide but this did not achieve statistical significance (P = 0.14). The probability of CR on HOPE-Bleo was examined with respect to the responses achieved with previous chemotherapy regimens ( Table IV) . If the durations of PR and NR are scored as zero then the association between chance of CR on HOPE-Bleo and the duration of previous remissions was marginally significant (P = 0.053). We could not show that the duration of the longest previous complete remission to any treatment influenced outcome in this study although the numbers are small.
Five patients who responded to HOPE-Bleo proceeded to high dose consolidation chemotherapy with autologous bone marrow grafting (the high dose melphalan and MBE regi- Comparison with existing reports is always difficult because of the differing patient populations studied. However, the majority of patients in this series had extranodal disease and B symptoms, the CR rate achieved suggests that the activity of HOPE-Bleo is probably as great as that of the ABVD regimen with a similar number of prolonged remissions (see Canellos et al., 1987 for review) . As expected the complete remission rate and the probability of a long term remission were both related to the previous sensitivity of the patient's disease to treatment and to the amount of previous chemotherapy received, as judged by the number of regimens and the previous use of drugs other than those included in the basic MOPP regimen or its variants. These data and the available literature do not, however, allow us to conclude with certainty that second line treatment with adriamycin containing combinations is superior to retreatment with MOPP-based regimens for patients relapsing from a long MOPP-induced CR (Fisher et al., 1979; Canellos et al., 1987) .
These data with long follow-up in a moderate number of relapsed patients suggest that HOPE-Bleo might prove to be as effective as the ABVD regimen as a primary treatment for Hodgkin's disease, and in view of its ease of administration, modest acute toxicity and low probabilty of carcinogenesis or infertility we feel that this possibility should be further explored. The results of studies where MOPP or related regimens are alternated with etoposide containing regimens similar to HOPE-Bleo are awaited with interest and preliminary results are encouraging (M. Cullen and B. Hancock, personal communications).
Some lessons can be inferred from the results of this study for the management of Hodgkin's disease in relapse. Overall only a small proportion of patients who relapse following chemotherapy are likely to be cured by a subsequent combination chemotherapy regimen. Nevertheless, eight patients in this study, who had had only one or two previous treatment regimens, have achieved long disease-free intervals and are probably cured. The most powerful factors predicting for a good prognosis are, in combination, a small amount of previous chemotherapy and a long previous remission, and among 19 patients, in this study, who had relapsed from complete remission achieved by a single previous chemotherapy regimen, six (32%) achieved long-term complete remission.
These results suggest caution in the use of intensive and dangerous consolidation treatment such as high dose chemotherapy with autologous bone marrow transplantation (Zulian et al., 1989; Russell et al., 1989; Canellos et al., 1987) . Patients who enter CR on initial chemotherapy, relapse and then re-enter CR on second line chemotherapy have about a 30% chance of achieving long remission or cure and for such patients a policy of observation, perhaps with marrow cryopreservation, may be advisable. If, however, a patient fails to enter CR or has relapsed from CR more than once, and has B symptoms and extra nodal disease then the prognosis is very poor and the place of intensive consolidation should be considered. Such policies can now be tested in randomised prospective trials.
